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Objective—Evaluate a computerized intervention supporting antiretroviral therapy (ART)
adherence and HIV transmission prevention.
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Settings—An academic HIV clinic and a community-based organization in Seattle.
Subjects—240 HIV-positive adults on ART; 209 completed nine-month follow-up (87%
retention).
Intervention—Randomization to computerized counseling or assessment-only, 4 sessions over 9
months.
Main Outcome Measures—HIV-1 viral suppression, and self-reported ART adherence, and
transmission risks, compared using generalized estimating equations.
Results—Overall, intervention participants had reduced viral load (VL): mean 0.17 log10
decline, versus 0.13 increase in controls, p = 0.053, and significant difference in ART adherence
baseline to 9 months (p = 0.046). Their sexual transmission risk behaviors decreased (OR = 0.55,
p = 0.020), a reduction not seen among controls (OR = 1.1, p = 0.664), and a significant difference
in change (p = 0.040).
Intervention effect was driven by those most in need: among those with detectable virus at
baseline (>30 copies/milliliter, n=89), intervention effect was mean 0.60 log10 VL decline versus
0.15 increase in controls, p=0.034. ART adherence at the final follow-up was 13 points higher
among intervention participants versus controls, p = 0.038.
Conclusions—Computerized counseling is promising for integrated ART adherence and safer
sex, especially for individuals with problems in these areas. This is the first intervention to report
improved ART adherence, viral suppression, and reduced secondary sexual transmission risk
behavior.
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INTRODUCTION
Antiretroviral therapy (ART) reduces morbidity and mortality related to human
immunodeficiency virus (HIV) infection. Sustained adherence to ART improves individual
outcomes and reduces secondary transmission, since low viral load is associated with
reduced HIV transmission1-3 and earlier ART initiation reduces sexual transmission by
96%.4 It is important to identify efficient ways to support medication adherence over a
lifetime, as ART is now recommended in the United States (US) for all persons living with
HIV (PLWH) regardless of CD4 count.5 However, only an estimated 77% of US patients on
ART have suppressed viral loads.6 Reducing transmission risk behaviors among PLWH
(‘prevention with positives’) is a longstanding public health goal.7 The chronicity of HIV
infection may be accompanied by continued or increased sexual risk behaviors for some
individuals; however, not all providers routinely address HIV transmission risk reduction
with their HIV-positive patients.8-10
Scalable strategies are needed to optimize ART adherence and to reduce secondary
transmission of HIV. Meta-analyses show that interventions to support ART adherence,11,12
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and to reduce secondary HIV transmission risk,13,14 are efficacious. Because these
interventions have been largely research-based, and staff- and resource-intensive,15,16
population-level implementation may not occur17.18
We hypothesized that a computer-delivered intervention could support ART adherence and
reduce HIV transmission risk by PLWH. We evaluated such an intervention called
Computer Assessment & Rx Education for HIV-positive people (CARE+).
METHODS
Participants
Study participants were recruited from a university-affiliated public HIV clinic and a large
AIDS service organization in Seattle, Washington. Eligibility criteria included age ≥18
years, on ART, able to understand spoken English; exclusions included thought disorders
and current participation in ART adherence or prevention-with-positives studies. Written
consent was obtained prior to randomized assignment. All procedures were approved by
University of Washington Human Subjects Division, 06-1198-C. Participants received $20
at the first three, and $40 at the final, session.
Intervention
Design—The computerized-counseling intervention was evaluated in a prospective two-
arm randomized controlled trial (RCT). The study sample of n=240 was assigned via an
automated pseudo-random number generation algorithm, disallowing any exposure to
intervention by controls. The experimental group received CARE+ (audio-narrated
assessment, tailored feedback, skill-building videos, health plan, and printout) on a tablet
computer and standard care, while controls received assessment only on tablets and standard
care. Each group underwent four sessions specific to assigned arm at three-month intervals
over nine months. Sessions were scheduled on same day as clinic visits wherever possible.
CARE+ is a .NET-based (Microsoft, Redmond, WA) custom software application on
touchscreen computers. Intervention content is based on theoretical frameworks:
information-motivation-behavior including ‘importance’ and confidence’ scales around
ART use and transmission risk-reduction,19 transtheoretical including stage of change
questions around condoms,20 social cognitive role-modeling with peers demonstrating
healthy behaviors in videos,21 and motivational interviewing including messages
acknowledging ambivalence around behavior change and highlighting user’s
commitment22). The tool incorporates evidence-based elements shown in RCTs to improve
ART adherence or reduce sexual risk,23,24 such as feedback including consequence-framed
messages (e.g., “Unprotected sex may expose you to STDs”)25 and videos.26 Content
recommendations were obtained through 30 qualitative interviews conducted with PLWH.27
Final CARE+ content was reviewed by an expert panel for face validity.
Figure 1 summarizes the CARE+ session. Users received tailored feedback based on risk
assessment responses, and viewed video versions for heterosexuals or for men who have sex
with men (MSM) showcasing skills around HIV disclosure, ART adherence, safer sex,
substance abuse, male/ female condoms, condom use negotiation, working with providers,
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and HIV natural history and ART mechanisms. Users develop a plan for ART adherence or
safer sex (user choice at 1st session, and switched at 3rd session). A personalized printout
summarized feedback, health plan, and referral phone numbers.
The control condition comprised computerized risk-assessment only (sexual behaviors,
substance use, mental health, ART regimen, side effects, adherence in last 7 and 30 days).
In both study arms, the tool flagged reports of severe depression by Patient Health
Questionnaire (PHQ-9 score of ≥20),28 intimate partner violence (IPV), or suicidal ideation;
as outlined in the consent, study staffers notified case managers for appropriate follow-up.
At repeat sessions, these participants were asked how referrals went. All intervention
participants were reminded of their last plan and asked to continue or make a new health
plan. Software usability was evaluated among an additional 30 HIV-positive clients, and one
week test-retest reliability assessment was done to establish psychometric performance of
key tool variables.29
Outcome Measures
The primary biological outcome was HIV-1 RNA viral load (VL), determined using a 500
microliter (mL) plasma specimen in a TaqMan real-time polymerase chain reaction assay
with 30 copies/microliter (mL) as the lower limit of quantification for detectable HIV-1.
HIV-1 viral load was assessed using specimens drawn on day of study interview or as part
of patient care within a month prior to study visit. The same laboratory was used for all
study and clinical viral loads and was determined by personnel blinded to study arm.
Primary behavioral outcome measures collected by self-report in both arms consisted of a
composite variable of sexual transmission risk – no condom use (unprotected sex) or
condom use with problems/errors (i.e., vaginal or anal sex either without a condom or where
a condom was used but HIV exposure may have occurred due to mechanical or user failure)
– and ART adherence by 30-day visual analog scale (VAS).30,31. Accurate reporting was
encouraged during enrollment, consent, and sessions through normalizing language and
reiteration that the study would not share self-reported data to providers, with sole exception
of IPV, severe depression, and suicidality, which (as noted in the consent) prompted
appropriate provider referral. Secondary outcome measures included changes in ART/
condom stage of change and HIV disclosure.
Statistical Methods
Fisher’s exact and Wilcoxon rank sum tests assessed differences between intervention and
control groups and between study sites in baseline study population characteristics. We
utilized generalized estimating equation (GEE) models with a Gaussian link and an
unstructured correlation structure to compare changes in viral load (log10-transformed) and
ART adherence (30-day VAS) between intervention and control groups and from baseline to
nine-month follow-up. GEE models with a logit link and an unstructured correlation
structure compared odds of undetectable viral load and sexual transmission risks between
intervention and control groups and from baseline to nine-month follow-up. All GEE models
included main effects for intervention condition and linear trend as well as an interaction
between these terms to capture differences in change between intervention conditions. The
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analysis was intent-to-treat. Covariates in the models included likely depression diagnosis
by PHQ-9 since this was the only variable that differed significantly between study arms at
baseline, as well as education, condom use with main partner at baseline, and study site.
These analyses were done for the whole sample, and for the subgroup who had detectable
viral load at baseline. Estimates for these ‘detectables’ were obtained by including relevant
main and interaction effects for an indicator variable specifying whether each participant
had detectable viral load at baseline. When modeling odds of viral load being undetectable
within this subgroup, only the three follow-up assessments were included. Analyses were
performed using R,32 including geepack33 for GEE, doBy34 for post-estimation, and
ggplot235 for result visualization.
RESULTS
We approached 301 individuals at two study sites; 240 enrolled (80% acceptance), 239
completed baseline, and 87% (209/239) were retained for nine-month study duration (Fig.
2). Participants were consented, enrolled, then randomized. The 30 lost to follow-up had
similar numbers and reasons across arms, suggesting non-differential dropout (p = .56 for
attrition by arm).
Table 1 shows participant characteristics at baseline by study arm. At baseline intervention
participants were less likely than controls to obtain a positive screening result for likely
depression diagnosis (n=14 vs. 25, p = 0.032). There were several significant differences at
baseline between clinic- and organization-recruited participants including proportion of
MSM, proportion incarcerated more than one night, condom use, self-reported ART
adherence (VAS), proportion with resistant virus, and proportion victimized by intimate
partner violence [Supplemental Table 1].
Figure 3 shows 95% confidence intervals for outcome means by time and study condition.
Detailed GEE results are in Supplemental Digital Content Tables 2-4 showing impact on
VL, proportion with undetectable VL, ART adherence, and sexual transmission risks in the
full sample [Supplemental Table 2] and the subset of participants with detectable VL at
baseline [Supplemental Table 3], as well as contrasts between intervention and control
conditions at each time point and between baseline and nine-month time points within each
condition, for full and subset samples [Supplemental Table 4].
Figure 4 summarizes main outcomes of interest. The first four contrasts in each figure are
intervention versus control at each time point while the last two contrasts in each figure
compare baseline with nine-month follow-up within each study arm.
HIV-1 Viral Load Effect
Figure 4a shows 95% confidence intervals for log10 viral load point-in-time study condition
mean differences and change within each group from baseline to nine-month follow-up.
Figure 4b shows 95% confidence intervals for point-in-time study condition differences and
change within each group from baseline to nine-month follow-up in the odds of having
undetectable viral load. There were marginally significant differences in change from
baseline to the nine-month follow-up between study arms in log10 viral load (p = 0.053) and
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in the odds of having undetectable viral load (p = 0.090). CARE+ intervention participants
overall had an average decrease of 0.17 log10 viral load (p = 0.112; 95% CI: −0.39–0.04)
while control participants had an increase of 0.13 (p = 0.250; 95% CI: −0.09–0.35) [Fig. 4a
Right]. Relative to baseline, the odds of having undetectable viral load at the nine-month
follow-up were increased in the CARE+ condition (OR = 1.57; p = 0.037; 95% CI: 1.03–
2.39) but reduced in the control condition (OR = 0.98; p = 0.925; 95% CI: 0.71–1.37) [Fig.
4b Right]. At the nine-month follow-up, CARE+ intervention participants were lower than
controls in log10 viral load (−0.06; p = 0.741; 95% CI: −0.4 −0.30) and had increased odds
of undetectable viral load (OR = 1.03; p = 0.920; 95% CI: 0.58–1.81), but neither of these
differences were significant.
Among the subgroup who had detectable viral load at baseline, CARE+ intervention
participants had an average decrease of 0.60 log10 viral load (p = 0.004; 95% CI: −1.01–
−0.19) [Fig. 4a Left] while control participants had an increase of 0.15 log10 viral load (p =
0.641; 95% CI: −0.48–0.78). At the nine-month follow-up, CARE+ intervention participants
were lower than controls in log10 viral load (−0.73; 95% CI: −1.42– −0.03), a significant
difference (p = 0.041) [Fig. 4a Left]. CARE+ intervention participants also had higher odds
of undetectable viral load than controls at the nine-month follow-up (OR= 2.32; 95% CI:
0.85–6.34), although this difference was only marginally significant (p = 0.101) [Fig. 4b
Left]. For the subgroup with detectable viral load at baseline, in Figure 4b we do not show
odds ratios for the baseline time point nor changes from baseline to the nine-month follow-
up time point within each group, because all of the participants in this subgroup had
detectable viral load at baseline. For the log10 viral load outcome, the three-way interaction
between baseline detectable VL, study arm, and time was significant (p = 0.034), indicating
CARE+ was more effective than control for those with detectable viral load at baseline
[Supp. 6].
ART Adherence Effect
Figure 4c shows 95% confidence intervals for point-in-time VAS mean differences between
groups and mean change within each group from baseline to nine-month follow-up. There
was a statistically significant difference in change from baseline to the nine-month follow-
up between study arms (p = 0.046) in self-reported ART adherence by 30-day VAS
[Supplemental Content 2]. CARE+ intervention participants had an average increase of 4.71
points in the percentage of medication doses taken (p = 0.014; 95% CI: 0.95–8.48) while
control participants had a decrease of 1.39 points (p = 0.556; 95% CI: −6.03–3.24) [Fig. 4c
Right]. At the nine-month follow-up, CARE+ intervention participants were higher than
controls in ART adherence (4.77; 95% CI: − 0.79–10.33), but this difference was not
significant (p = 0.093) [Fig. 4c Right].
Among those with detectable viral load at baseline, CARE+ intervention participants had an
average VAS adherence increase of 8.00 points (p = 0.040; 95% CI: 0.37–15.62) while
control participants had a decrease of 1.53 points (p = 0.822; 95% CI: −14.84–11.78) [Fig.
4c Left]. At the nine-month follow-up, CARE+ intervention participants were higher than
controls in ART adherence (13.44; 95% CI: 0.73–26.14), a significant difference (p = .038)
[Fig. 4c Left].
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Secondary HIV Transmission Risk Effect
Figure 4d shows confidence intervals for point-in-time study condition differences and
change within each group from baseline to nine-month follow-up in self-reported
transmission risks, defined as sex without a condom or condom use with errors. There was a
statistically significant difference in change from baseline to the nine-month follow-up
between study arms in self-reported transmission risks (p = 0.040). Among CARE+
intervention participants, the odds of transmission risks were 0.55 times lower at the nine-
month follow-up than at baseline (p = 0.020; 95% CI: 0.34–0.91) while for control
participants the odds of transmission risks increased over time (OR = 1.10; p = 0.664; 95%
CI: 0.72–1.67) [Fig. 4d Right]. At the nine-month follow-up, CARE+ intervention
participants had a reduced odds of transmission risks when compared with controls (OR =
0.46; 95% CI: 0.25–0.84), a significant difference (p = .012) [Fig. 4d Right].
Clinic Site and Detectable Viral Load at Baseline as Effect Modifiers
None of the three-way interactions involving study arm, linear trend, and clinic site were
statistically significant, suggesting similar intervention effects in the university-affiliated
and community-based organization sites (Supplement 5). Detectable viral load at baseline
was a modifier of study arm effects on log10 viral load, as indicated by a significant three-
way interaction between study arm, linear trend, and detectable viral load at baseline (p =
0.034). Three-way interactions involving study arm, linear trend, and detectable viral load at
baseline were not statistically significant for other outcomes (Supplement 6).
Health Promotion Behavior Plans
CARE+ intervention participants made a concrete plan for ART adherence or transmission
risk reduction (controls did not make plans). Many individuals (78%) indicated at baseline
that they had an approach that was working for them, which they detailed with specific steps
in the CARE+ session; 12% made a new plan. Common plans for ART adherence were to
‘keep doing what I am doing’ (n = 32) ‘use reminders’ (31), and ‘get support’ (25).
Common plans for transmission risk reduction were to ‘not have sex’ (31), ‘use condoms’
(27), ‘have fewer or only 1 sex partner(s)’ (22), or ‘only have sex with people who are also
positive’ (7).
Intervention participants’ confidence in their plan success increased over time, from 66% at
three months to 80% at nine months (McNemar’s χ2 p = .02). Confidence in their ability to
not transmit HIV increased over time: 0-10 ascending scale for confidence, mean 8.43 (SD
2.27) at baseline and 9.14 (SD 1.53) at nine months, p = .02.
At baseline, 41 referrals were made for intervention participants and 52 for controls for
reported severe depression (37%), IPV (9%), or suicidal ideation (53%); at nine months total
referrals for these conditions were 21 and 32, respectively (p = .10).
Intervention Acceptability
Nearly all (97%) CARE+ intervention participants found the tool easy to use; 99% rated
session length as “just right”; 97% felt they had “enough privacy” during the session. Most
(93%) felt the CARE+ session helped them as much or more than face-to-face counseling
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with a staff person, and 75% said they would prefer the computer over a human counselor in
the future. No harms or unintended effects were noted in either arm of the study.
DISCUSSION
We found that a computerized counseling tool was effective at helping PLWH improve ART
adherence and reduce HIV transmission risk behaviors, as measured by improvement in self-
reported adherence, reduction in viral load, and improvement in reported correct and
consistent condom use, compared to controls receiving usual care. The adherence effect was
most pronounced among those whose plasma HIV-1 was not suppressed at baseline. The
reduced viral load and fewer sexual transmission risk behaviors seen among those
undergoing the intervention both may contribute to decreasing HIV transmission to sexual
partners.
In our study population area, chart audits found that fewer than half of HIV-positive clients
were assessed for sexual risks, STD testing or referral.36 Another study assessing 26 HIV
clinics across the US found that providers reported delivering prevention-with-positives
counseling at 67% of initial visits but only 53% of subsequent regular visits.37
Computerized counseling may lack some advantages offered by a highly-skilled human
counselor, but it is delivered consistently with fidelity,38 without need for staff time or
training. In our study it proved highly acceptable and had an efficacious impact on priority
behaviors and objective measures of viral load response.
Multiple studies have utilized computers to assess ART non-adherence,39-41 or HIV
transmission risk42-48 among PLWH, but fewer have been used to influence patient
behavior.49,50 Lightfoot found that computer-assisted self-monitoring of transmission risk
behaviors can be a strategy for PLWH.51,52 Fisher et al. found that computerized counseling
supported ART adherence though this study did not find a viral load impact.53 Others have
used computerized counseling to reduce HIV acquisition risk,54-56 which meta-analyses
have found to be effective.57
Economic evaluation models have found that adherence interventions with modest
effectiveness may provide survival benefit to patients and be cost-effective.58 The
intervention we tested that does not require staff time, training, and monitoring may be
easier to introduce into busy practice settings.
Study limitations include the fact that two-thirds of our population already had suppressed
VL at baseline and 60% did not engage in sexual activities at any timepoint. Both limitations
present conservative biases to the null. Mirroring the Seattle HIV epidemic, the sample was
predominantly male. This makes extension of these results to females, or to those living
outside the US, less generalizable. These were heavily treatment- and intervention-
experienced populations. Half the sample was from an HIV clinic whose approach to ART
adherence support was itself found to reduce log10 viral load.59 The potential for detecting
intervention effect, and magnitude of effect, may be greater in populations with lower ART
adherence or higher sexual risk at baseline.60 The study was well-powered to detect a
clinically meaningful intervention effect, i.e., a mean half-log10 change in viral load.
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However, given that this is one study, examining intervention effects in additional diverse
HIV-positive samples would contribute to important next steps of replication and
generalization. Future research could include examination of the interplay of multiple HIV
behaviors such as nonadherence and sexual risk. The intervention may have influenced risk
behavior reporting, though computerized approaches can reduce social desirability bias61
and the VL differences seen is consistent with differences in reported adherence behavior. In
previous work with the CARE platform users reported that it was easier to be honest with
the computer and that the session allowed them to reflect on recent risk behaviors.62 Self-
reports of sexual transmission risk outcomes and of ART adherence are limitations. Follow-
up of nine months did not allow evaluation of longer-term impact or effect duration. Though
the study was conducted in a period when there were fewer ART regimens available,
inconsistent ART adherence even to current simplified regimens continues to be a major
challenge.63
The study was strengthened by including community- and clinic-based samples, which had
similar intervention effects, increasing generalizability.
CONCLUSION
Computer-delivered counseling had a modest, but significant, positive impact on HIV-1
viral load—a primary driver of morbidity and genital compartment infectivity64—and on
self-reported HIV transmission risks. This was particularly the case for those who had non-
suppression of viral load at baseline – precisely the highest-need group in whom an
intervention can have impact. This group’s average VL at baseline declined by a clinically
meaningful reduction of approximately 0.5 log10 a reduction that has implications for the
person’s own health as well as infectiousness. Their reported ART adherence increased by
around 10% (76% at baseline to 85% at 9-months), whereas controls started at 74% mean
adherence and showed no improvement over time. The intervention’s relatively modest
absolute changes were enough to get this vulnerable group into better ranges of medication
adherence, as seen by viral load impact. The importance of supporting treatment adherence
has been highlighted by Gardner and others who have shown how few HIV-positive
individuals even in care are virally suppressed in the US.65 Interventions to support
adherence have tended to show relatively small effects, highlighting the need for efficacious
interventions that can be implemented without straining health system resources,63 as is the
promise of computerized counseling tools such as CARE+.
As far as we know this is the first ART adherence and secondary HIV transmission risk
intervention to find biological effect (viral load) and behavioral impact among persons
living with HIV. The computer format was highly acceptable and facilitated delivery in busy
settings. Such an approach warrants further evaluation to determine utility in improving HIV
treatment outcomes and reducing secondary HIV transmission among persons living with
HIV.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CARE+ Computerized Counseling Intervention Content By Session
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CARE+ Computerized Counseling Intervention Trial, Four Sessions Over 9 Months
HIV denotes human immunodeficiency virus-1.
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Figure 3. Adjusted Means* by Time and Treatment Condition
* NOTE: For these independent 95% confidence intervals, non-overlap indicates p < .05, but overlap does not reliably indicate
that p > .05 (Cumming, 2009). See Fig. 4 for contrasts. Detectable BL: had detectable HIV1 viral load at first baseline (BL)
session Full sample: All participants regardless of viral load status at baseline
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Comparison of Viral Load, ART Adherence, and Unprotected Sex for Each Follow-up Point and Changes within each
Treatment Condition.
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Table 1













Female Gender 12 9 0.6732 NS
Age 45 (11) 45 (9.75) 0.7759 NS
Hispanic/Latino 9 8 0.8161 NS
American Indian or Alaska Native 12 12 1.0000 NS
Asian 1 3 0.2109 NS
Black or African-American 28 31 0.7765 NS
Native Hawaiian or Other Pacific Islander 0 2 0.2448 NS
White 57 53 0.6020 NS
Other Race 10 8 0.6488 NS
No High School (HS) Diploma/GED 15 14 1.0000 NS
HS Diploma/GED Only 50 39 0.0919+ NS
More than High School 35 47 0.0862+ NS
Man Who Has Sex with Men 72 77 0.3738 0.0118 *
Incarcerated More Than One Night 45 53 0.2452 0.0280 *
Injecting Drug Use Past 3 Months 17 10 0.1831 NS
Any Methamphetamine 20 13 0.1610 NS
Any Cocaine 19 22 0.6338 NS
Any Methamphetamine or Cocaine 34 28 0.3279 NS
Any Sex Past 3 Months 61 59 0.7926 NS
No Condom with Main Partner 8 15 0.0688+ NS
No Condom with Other Partner 12 16 0.4648 NS *
Unprotected Discordant Sex with Main
Partner
2 1 1.0000 NS
Unprotected Discordant Sex with Other
Partner
2 5 0.3333 NS
Condom Use with Problems 14 11 0.5588 NS
Any Sex without Condoms 19 27 0.1693 0.0310 *
Any Sex without Condoms or with Condom
Problems
29 34 0.4879 0.0508 +
Adherence Visual Analog Scale (VAS) 94.5 (12.25) 93 (15) 0.4189 0.0357 *
96%+ VAS Adherence 43 44 0.8952 0.0173 *
90%+ VAS Adherence 69 70 0.8874 0.0152 *
86%+ VAS Adherence 76 74 0.8798 0.0150 *
80%+ VAS Adherence 83 83 1.0000 NS
70%+ VAS Adherence 87 90 0.5463 NS


































Missed Doses Past 7 Days 0 (1) 0 (1) 0.6648 NS
CD4 Nadir 125.5 (214.5) 91 (188.75) 0.4800 NS
Viral Load Before Medication 4.95 (2.24) 4.88 (2.39) 0.5201 NS
Ever Told Resistant Virus 16 17 0.8627 0.0348 *
Years Since HIV Diagnosis 12 (9.25) 11 (9.75) 0.3634 0.0503 +
Depression Severity (PHQ-9) 6 (10.5) 7 (14) 0.0969+ NS
Depression Diagnosis (PHQ-9) 14 25 0.0319* NS
Anxiety More than Half of Past 7 Days 31 29 0.7774 NS
Intimate Partner Violence (IPV) Perpetration 2 3 0.4462 NS
IPV Victimization 9 7 0.6336 0.0031 **
Past Adherence Intervention 7 3 0.3753 NS
Past Prevention with Positives Intervention 12 10 0.8359 NS
log10 HIV-1 Viral Load 1.48 (1.49) 1.48 (0.99) 0.1149 NS
Detectable Viral Load 44 33 0.1102 NS
CD4 394 (347.5) 341 (364.5) 0.4872 NS






p <.01. A log10 viral load of 1.48 is “undetectable”.
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